Management of Newborns with Prenatal Opioid Exposure: One Institution's Journey.


Journal

Clinical therapeutics
ISSN: 1879-114X
Titre abrégé: Clin Ther
Pays: United States
ID NLM: 7706726

Informations de publication

Date de publication:
09 2019
Historique:
received: 15 05 2019
revised: 28 06 2019
accepted: 02 07 2019
pubmed: 24 8 2019
medline: 12 6 2020
entrez: 24 8 2019
Statut: ppublish

Résumé

The prevalence of newborns with neonatal abstinence syndrome (NAS) is rising sharply. To respond to this crisis, our institution re-examined our policies and procedures regarding our approach to the management of newborns with prenatal opioid exposure. Our 6-pronged approach included: (1) a commitment to nonpharmacologic care as first-line treatment; (2) a simplified function-based approach to observation of the infant (Eat-Sleep-Console); (3) improved prenatal education to prepare parents for the newborn's postnatal course; (4) a cuddler program; (5) strategies to help parents remain at the bedside; and (6) change from morphine to methadone for infants who require medication for NAS. Our obstetrics collaborators and outpatient pediatric colleagues have partnered with us to prepare mothers for delivery by strengthening them in their recovery prenatally and helping them maintain their recovery after discharge. Among many improvements, our changes resulted in a decrease in medication treatment for NAS (from 87% to 40%), a decrease in the need for adjuvant medication (from 34% to 2%), and a decrease in length of hospital stay (from 18 days to 10 days). The 3 most significant factors that have contributed to our success have been: (1) a committed champion leader; (2) a strong collaborative multidisciplinary team; and (3) a quality improvement approach that facilitates implementation of ideas easily and provides timely feedback to guide further change. Although we have seen notable improvements with our new approach, emerging data from our outpatient colleagues indicate that much more is needed to help improve the long-term health of these dyads.

Identifiants

pubmed: 31439335
pii: S0149-2918(19)30344-3
doi: 10.1016/j.clinthera.2019.07.001
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Morphine 76I7G6D29C
Methadone UC6VBE7V1Z

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1663-1668

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Susan Minear (S)

Department of Pediatrics, Boston Medical Center, Boston, MA, USA. Electronic address: susan.minear@bmc.org.

Elisha M Wachman (EM)

Department of Pediatrics, Boston Medical Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH